Clinical Trial Update: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment [Phase 1]

View source ↗

Summary

A Phase 1 study of NP-101 in patients with unresectable hepatocellular carcinoma undergoing Y-90 treatment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• NP-101

Snippet

Sponsor: University of Florida | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: WITHDRAWN